Compare Trade Desk Inc (TTD) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trade Desk Inc vs Zimmer Biomet Holdings Inc — how do they compare? Trade Desk Inc trades at $12.08 (market cap $5.83B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.9× Trade Desk Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Trade Desk Inc for 72 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| TTD | ZBH | |
|---|---|---|
Market Cap | $5.83B | $16.95B |
Volume | 15,864,392 | 2,505,240 |
Sector | Media | Health |
52-Week High | $54.13 | $103.98 |
52-Week Low | $11.92 | $79.58 |
Typical Hold Time | 72 Days | 89 Days |
Enterprise Value | $4.78B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The Trade Desk (TTD) trades at $12.34, up 2.07% today but remains down significantly from recent highs. Technical indicators show a bearish trend with mixed momentum signals. Fundamentally, the company maintains strong profitability with 76.87% gross margins and 15.44% ROE, though revenue growth has slowed to 3% in 2026. Recent news highlights competitive pressures from Amazon and Alphabet while the company navigates workforce reductions and slower CTV growth.
Investment outlook remains cautious with analyst consensus at $14.72 target price representing 19% upside potential. Key opportunities include TTD's dominant position in programmatic advertising and healthy cash flow generation. Primary risks involve intensifying competition from tech giants, slowing revenue growth, and execution challenges during restructuring. The stock presents a value opportunity for patient investors if competitive pressures ease.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
